SCHEMBL3334136

SCHEMBL3334136

CC1CC2=C(O1)c1ccc3ccc(Cl)cc3c1C(=O)C2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.43
TYMS P04818 6/20 0.36
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
CHEK1 O14757 1/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CES2 O00748 1/20 0.33
KDM1A O60341 1/20 0.33
ACHE P22303 1/20 0.33
CES1 P23141 1/20 0.33
PTPN6 P29350 1/20 0.33
PTPN11 Q06124 1/20 0.33
ELAVL1 Q15717 1/20 0.33
HIF1A Q16665 1/20 0.33
EPAS1 Q99814 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327389 0.87 STAT3 (0.50) STAT3TYMSBRD4CREBBPMEN1
SCHEMBL3327381 0.83 DNMT1 (0.50) STAT3MEN1KMT2ATDP1CES2
SCHEMBL25704302 0.78 TYMS (0.33) TYMSBRD4CREBBPCHEK1CNR1
SCHEMBL25704277 0.76 STAT3 (0.45) STAT3TYMSBRD4CREBBPACHE
SCHEMBL3330784 0.72 STAT3 (0.43) STAT3MEN1KMT2ATDP1CES2
SCHEMBL8047458 0.72 DNMT1 (0.40) STAT3MEN1KMT2ATDP1CES2
SCHEMBL31177969 0.69 MAOA (0.54) STAT3MEN1KMT2ATDP1KDM4E
SCHEMBL29135713 0.69 STAT3 (0.53) STAT3BRD4CREBBPIDO1MAOA
SCHEMBL29199272 0.69 STAT3 (0.59) STAT3BRD4CREBBPIDO1MAOA
SCHEMBL1230608 0.69 MAOA (0.54) STAT3MEN1KMT2ATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404869-B2 Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome MAZENCE INC. (KR) 2013-03-26 US claimed
US-20100137422-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME YUNGJIN PHARM. CO., LTD. (KR) 2010-06-03 US claimed
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS NADIANBIO LTD. (KR) 2023-08-17 US disclosed
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS NADIANBIO LTD. (KR) 2023-08-17 US disclosed
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE KWAK TAEHWAN (KR) 2014-06-05 US disclosed
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE KWAK TAEHWAN (KR) 2014-06-05 US disclosed
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES KT & G CORPORATION (KR) 2013-11-14 US disclosed
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES KT & G CORPORATION (KR) 2013-11-14 US disclosed
US-20120289577-A1 COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS KT&G LIFE SCIENCES CORPORATION (KR) 2012-11-15 US disclosed
US-20120289577-A1 COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS KT&G LIFE SCIENCES CORPORATION (KR) 2012-11-15 US disclosed
US-20120114714-A1 METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION KWAK TAEHWAN (KR) 2012-05-10 US disclosed
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM KT & G CO., LTD. (KR) 2010-09-16 US disclosed
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM KT & G CO., LTD. (KR) 2010-09-16 US disclosed
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND KT&G CO., LTD. (KR) 2010-08-19 US disclosed
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND KT&G CO., LTD. (KR) 2010-08-19 US disclosed
WO-2009084834-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE MAZENCE INC. (KR) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES REN, ATP6V1B1, SLC5A1 STAT3 3921/4885TYMS 3616/4885BRD4 4736/4885
US-20120114714-A1 METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION PDE3A, PDE3B, PDE2A STAT3 4526/4885TYMS 2974/4885BRD4 4036/4885
US-20120289577-A1 COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS NQO1, MT-ND6, MT-ND5 STAT3 4645/4885TYMS 1611/4885BRD4 1442/4885
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS PDCD1, CD274, PDCD10 STAT3 1876/4885TYMS 1332/4885BRD4 1642/4885
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM SLC10A2, SI, ABCB11 STAT3 1970/4885TYMS 775/4885BRD4 2552/4885
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE TNNT2, TNNC1, TNNI3 STAT3 3416/4885TYMS 3116/4885BRD4 4452/4885
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND NDUFB10, NDUFB7, SQLE STAT3 4698/4885TYMS 2370/4885BRD4 3004/4885
US-20100137422-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME CYP27A1, CYP46A1, PCSK9 STAT3 2974/4885TYMS 1533/4885BRD4 3055/4885
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KLK3, NR5A1, MAN2B2 STAT3 2557/4885TYMS 503/4885BRD4 3558/4885
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE PDE3A, PDE3B, PDE2A STAT3 4761/4885TYMS 1980/4885BRD4 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.